Intermittent Asthma and Risk of Severe Exacerbation in Children

Area of Science:

• Pediatric Pulmonology
• Asthma Management
• Public Health

Background:

• Current GINA guidelines recommend against using short-acting beta-agonists (SABA) alone for mild asthma due to severe exacerbation risks.
• It remains unclear if all mild asthma patients share an equal risk for severe exacerbations.

Purpose of the Study:

• To identify if a specific subgroup of mild asthma patients exhibits a very low risk of severe asthma exacerbations.
• To evaluate the cost-effectiveness of current treatment guidelines for this identified low-risk subgroup.

Main Methods:

• A cohort of 2-18 year olds with intermittent asthma was identified from Ohio Medicaid claims data over three years.
• A low-risk group was defined based on SABA canister dispensing in the first two years.
• The third year compared severe asthma exacerbation risks between the low-risk group and the rest of the cohort.

Main Results:

• 13,208 patients met inclusion criteria. The low-risk group (3,935 patients) had significantly lower rates of hospitalization (0.08%) and ED/UC visits (0.97%/0.55%) with 0-2 SABA canisters/year.
• Relative risk of hospitalization was 0.17 (95% CI: 0.06, 0.52) and severe exacerbation was 0.18 (95% CI: 0.13, 0.27) in the low-risk group compared to high-risk patients.
• Preventing one hospitalization in the low-risk cohort required treating 5,535 patients, costing $779,716 per hospitalization prevented with ICS therapy.

Conclusions:

• A subgroup of mild asthma patients exists with a demonstrably lower risk of hospitalization and severe exacerbations.
• Current GINA first-step treatment recommendations may be unnecessary and not cost-effective for this identified low-risk population.
• Further research into personalized asthma management strategies based on risk stratification is warranted.